M. Spengler

Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone

M Hanefeld, Sabine Fischer, Jan Schulze et al. · Diabetes Care · 1991 · 180 citations

Nutrition, Pharmacotherapy, Metabolic Syndrome +19

Efficacy of 24-Week Monotherapy With Acarbose, Metformin, or Placebo in Dietary-Treated NIDDM Patients

Jürgen Hoffmann, M. Spengler · The American Journal of Medicine · 1997 · 145 citations

Pharmacology, Treatment Option, 24-Week Monotherapy +5

Efficacy of 24-Week Monotnerapy With Acarbose, Glibenclamide, or Placebo in NIDDM Patients: The Essen Study

Juergen Hoffmann, M. Spengler · Diabetes Care · 1994 · 144 citations

Effect of Starch Malabsorption on Colonic Function and Metabolism in Humans

W Scheppach, Claudia Fabian, Frank Ahrens et al. · Gastroenterology · 1988 · 74 citations

Nutrition, Biochemistry, Food Digestion +10

European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses

Sabine Fischer, M Hanefeld, M. Spengler et al. · Acta Diabetologica · 1998 · 72 citations

Pharmacological Study, Diabetes, Pharmacology +6